What is SHARe?

A 12-member consortium launched by the CCTS to build on the strengths of our Partner Network to develop a truly transformational research enterprise in multisite studies for the Deep South.

Who is in SHARe?

Auburn University, HudsonAlpha Institute for Biotechnology, Louisiana State University Health Sciences Center, Ochsner Health System, Pennington Biomedical Research Center, Southern Research, Tulane University, Tuskegee University, University of Alabama, University of Alabama at Birmingham, University of Mississippi Medical Center, and University of South Alabama.

Why Use SHARe?

  • Multisite studies and clinical trials require a high degree of coordination among study sites. SHARe reduces the redundancies and eases the administrative burdens that slow typical time-to-activation. For instance, all 11 CCTS Partners have signed on to a master IRB reliance agreement, streamlining the review process.
  • Multisite studies and clinical trials frequently struggle with recruitment. SHARe offers access to a large, regional, and diverse patient population. Whether you are studying a rare or chronic disease, looking for a genetic anomaly, or testing the effects of an intervention or treatment by gender, age, race/ethnicity, socioeconomic status, or geographic location, the SHARe network increases the odds of quickly building a robust list of potential participants who meet your research criteria.
  • Multisite studies and clinical trials that participate in SHARe will help spur trans-network innovation among faculty, physicians, and other health care providers, resulting in discoveries that can rapidly improve health care and, ultimately, benefit communities across the region.

How Do I Propose a Study to SHARe?

Principal investigators from across any SHARe institution who are interested in proposing a study should contact the SHARe lead for more information.

 SHARe Trials Initiated

In our first year, SHARe facilitated eight studies--a sample of these are listed below.

  STUDY TITLE   PARTICIPATING SHARe SITES (*lead site)
  Olanzapine for CINV in Patients Undergoing Multi-Day,
High Dose Chemotherapy Prior to SCT
  Ochsner, Tulane, UAB*, UMMC 
  Antihypertensives for Mild Chronic Hypertension during
Pregnancy: A Pragmatic Multicenter Randomized Trial 
  Ochsner, Tulane, UAB*, UMMC
Arkansas - CTSA
  Do Health Disparities in the Deep South Impact
Neonatal Palliative Care?: Parents Perspectives
  Children’s Hospital New Orleans, LSU
Children's Hospital, UAB*
Batson Children's Hospital, UMMC
  Pembrolizumab in HIV and Relapsed, Refractory, or
Disseminated Malignant Neoplasms
  LSU*, UAB
  Safety and Effectiveness of Live Zoster Vaccine in
Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
  Ochsner (Baton Rouge & New Orleans), UAB*
  A Phase II Study of Cabozantinib for Recurrent or
Persistent Cervical Cancer
  USA* UAB, Tulane 

SHARe Advisory Committee

  PARTNER   PRINCIPAL   SECONDARY
  University of Alabama at Birmingham   Robert P. Kimberly, MD   Jason J. Nichols, OD MPH PhD
  Tulane University   ‘Tonette’ Krousel-Wood, MD MSPH   Roy Weiner, MD
Rachel Cruthirds
  Louisiana State University Health Sciences Center   Chris Parsons, MD    
  Pennington Biomedical Research Center   Daniel Hsia, MD   Brian Melancon
  University of South Alabama   Rod Rocconi, MD   Kim Littlefield, PhD
  University of Mississippi Medical Center   Richard L. Summers, MD   Gailen Marshall, MD
  Auburn University   Richard Hansen, PhD   Kathy Ellison, PhD
  University of Alabama   Bret Summerlin   Louanne Friend
  Turskegee University   Clayton Yates, PhD    
  Hudson-Alpha Institute for Biotechnology   Devin Absher, PhD    
  Southern Research